Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 9/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.46 |
| ▸ | FLT3 | P36888 | 6/20 | 0.46 |
| ▸ | CSF1R | P07333 | 3/20 | 0.46 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.46 |
| ▸ | PLK4 | O00444 | 2/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116963 | 0.90 | PDGFRB (0.46) | ALKKDRPRKAA1PDGFRBPRKAA2 | |
| SCHEMBL5518078 | 0.89 | ALK (0.50) | ALKKDRPRKAA1PDGFRBPRKAA2 | |
| SCHEMBL2114116 | 0.88 | LRRK2 (0.42) | ALKKDRPRKAA1PDGFRBPRKAA2 | |
| SCHEMBL2115792 | 0.86 | NTRK1 (0.43) | ALKKDRPDGFRBFLT3FGFR1 | |
| SCHEMBL6725660 | 0.84 | ALK (0.52) | ALKKDRPRKAA1PDGFRBPRKAA2 | |
| SCHEMBL2114117 | 0.83 | KDR (0.46) | KDRPDGFRBFLT3FGFR1SRC | |
| SCHEMBL2116248 | 0.81 | KDR (0.40) | KDRPRKAA1PDGFRBPRKAA2FLT3 | |
| SCHEMBL1673441 | 0.81 | ALK (0.52) | ALKKDRPRKAA1PDGFRBPRKAA2 | |
| SCHEMBL398243 | 0.81 | TLK2 (0.48) | KDRFLT3TLK2PDPK1NTRK1 | |
| SCHEMBL2115891 | 0.80 | MEN1 (0.48) | ALKKDRPDGFRBFGFR1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207756-A1 | ANTITUMOR AGENT FOR THYROID CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-25 | — | — | US | claimed |
| EP-2119707-A1 | COMPOSITION FOR TREATMENT OF UNDIFFERENTIATED-TYPE OF GASTRIC CANCER | Eisai R&D Management Co., Ltd. (JP) | 2009-11-18 | — | — | EP | claimed |
| US-20090264464-A1 | ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-22 | — | — | US | claimed |
| US-20090209580-A1 | ANTITUMOR AGENT FOR THYROID CANCER | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | claimed |
| EP-2065372-A1 | ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | claimed |
| EP-2036557-A1 | ANTITUMOR AGENT FOR THYROID CANCER | Eisai R&D Management Co., Ltd. (JP) | 2009-03-18 | — | — | EP | claimed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | claimed |
| EP-2036557-B1 | ANTITUMOR AGENT FOR THYROID CANCER | EISAI R&D MAN CO LTD (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-9006256-B2 | Antitumor agent for thyroid cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-8962655-B2 | Composition for treatment of undifferentiated gastric cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8865737-B2 | Antitumor agent for undifferentiated gastric cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| EP-2065372-B1 | ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER | EISAI R&D MAN CO LTD (JP) | 2012-11-28 | — | — | EP | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1259514-A2 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| US-6465507-B2 | ANTITUMOR AGENTS | SUGEN, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020042427-A1 | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | SUGEN, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001064681-A2 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209580-A1 | ANTITUMOR AGENT FOR THYROID CANCER | MEN1, VHL, NTSR2 | ALK 4653/4885KDR 2455/4885PRKAA1 2909/4885 |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | MKI67, CCNA1, CCNI | ALK 4375/4885KDR 3687/4885PRKAA1 3094/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | ALK 191/4885KDR 395/4885PRKAA1 881/4885 |
| US-20090264464-A1 | ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER | FGFR2, FGFR3, FGF2 | ALK 706/4885KDR 340/4885PRKAA1 1808/4885 |
| US-20020042427-A1 | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | MAP3K20, MAP3K6, MAP3K3 | ALK 774/4885KDR 936/4885PRKAA1 298/4885 |
| US-20110207756-A1 | ANTITUMOR AGENT FOR THYROID CANCER | MEN1, VHL, NTSR2 | ALK 4653/4885KDR 2455/4885PRKAA1 2909/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | ALK 1177/4885KDR 1372/4885PRKAA1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.